Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

Tegoprubart is a Game Changer in Islet Cell Transplantation Surgery for T1D Patients

Key Takeaway: The article highlights the potential of Tegoprubart in revolutionizing islet cell transplantation for Type 1 Diabetes (T1D) patients. It discusses how this treatment could significantly improve patient outcomes and transform lives. The focus is on the positive impact of Tegoprubart, supported by patient stories and clinical trial results.
Price reaction · baseline $2.27 (2026-02-23 close) · hit after-hours · 1 other ELDN headline(s) in the window, move may be shared
day 0 close
+7.9%
day 1
+8.8%
day 3 · peak
+15.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Tegoprubart shows promise in islet cell transplantation.
  • It has the potential to transform lives of T1D patients.
  • The article emphasizes patient success stories.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Transforming Lives. One Organ at a Time.
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What is Tegoprubart?

Tegoprubart is a treatment aimed at improving islet cell transplantation outcomes for T1D patients.

How does Tegoprubart benefit T1D patients?

It has the potential to transform lives by enhancing the success of islet cell transplants.

Are there any patient success stories?

Yes, the article highlights various patient stories showcasing the positive impact of Tegoprubart.

What is the focus of the article?

The article focuses on the promise of Tegoprubart in revolutionizing treatment for Type 1 Diabetes.

Last updated: Feb 23, 2026